Profile data is unavailable for this security.
About the company
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
- Revenue in ILS (TTM)43.35m
- Net income in ILS-182.80m
- Incorporated2003
- Employees79.00
- LocationBioline Rx LtdModi'in Technology Park2 HaMa'ayan StreetMODIIN 7177871IsraelISR
- Phone+972 86429100
- Fax+972 86429101
- Websitehttps://www.biolinerx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grace Breeding Ltd | 463.00k | -8.50m | 44.94m | -- | -- | 28.34 | -- | 97.05 | -2.36 | -2.25 | 0.1296 | 0.3998 | 0.0848 | 2.73 | 0.9636 | -- | -164.09 | -- | -206.24 | -- | 80.56 | -- | -1,935.21 | -- | 1.45 | -94.74 | 0.5103 | -- | 121.53 | -- | 23.10 | -- | -- | -- |
| X T L Biopharmaceuticals Ltd | 1.69m | -83.65m | 45.58m | 33.00 | -- | 0.5451 | -- | 26.99 | -0.3798 | -0.3798 | 0.0077 | 0.1535 | 0.0192 | -- | 0.7012 | 51,169.93 | -94.96 | -53.17 | -111.98 | -59.10 | -- | -2.33 | -4,953.75 | -1,084.42 | -- | -- | 0.00 | -- | -85.80 | -- | -7.97 | -- | -53.12 | -- |
| Cannassure Therapeutics Ltd | 11.00m | -1.18m | 50.23m | -- | -- | -- | 180.69 | 4.57 | -1.43 | -2.16 | 13.28 | -3.66 | 0.5329 | 1.37 | 4.47 | -- | -5.74 | -45.39 | -18.34 | -92.41 | 29.17 | -- | -10.77 | -83.49 | 0.0474 | 0.9011 | -- | -- | -67.44 | -- | 78.37 | -- | -72.23 | -- |
| Can Fite Biopharma Ltd | 2.76m | -28.39m | 55.83m | 5.00 | -- | 2.18 | -- | 20.20 | -0.0226 | -0.0226 | 0.0022 | 0.0171 | 0.0771 | -- | -- | 552,702.80 | -79.22 | -102.29 | -103.51 | -131.07 | -- | -- | -1,027.46 | -1,105.36 | -- | -- | 0.00 | -- | -8.27 | -27.92 | 24.96 | -- | -42.92 | -- |
| Purple Biotech Ltd | 0.00 | -69.79m | 59.53m | 20.00 | -- | 0.5149 | -- | -- | -0.2753 | -0.2753 | 0.00 | 0.42 | 0.00 | -- | -- | 0.00 | -40.57 | -37.24 | -47.99 | -41.28 | -- | -- | -- | -9,415.70 | -- | -- | 0.0098 | -- | -- | -- | 8.25 | -- | -28.45 | -- |
| Matricelf Ltd | 0.00 | -13.83m | 70.04m | -- | -- | 2.60 | -- | -- | -0.8777 | -0.8777 | 0.00 | 1.67 | 0.00 | -- | -- | -- | -39.69 | -- | -42.80 | -- | -- | -- | -- | -- | -- | -- | 0.0527 | -- | -- | -- | -10.77 | -- | -- | -- |
| DNA Group TR Ltd | 306.00k | -1.18m | 96.19m | 14.00 | -- | 1.21 | -- | 314.35 | -0.0088 | -0.0088 | 0.0025 | 0.6429 | 0.0038 | -- | 1.37 | 21,857.14 | -1.45 | -23.54 | -1.46 | -26.27 | -- | -- | -384.64 | -7,406.24 | -- | -- | 0.00 | -- | -45.36 | -- | 95.00 | -- | -- | -- |
| GFC Green Fields Capital Ltd | 0.00 | 15.70m | 123.57m | 2.00 | 7.90 | 0.7807 | 7.87 | -- | 1.56 | 1.56 | 0.00 | 15.77 | 0.00 | -- | -- | -- | 3.26 | 1.99 | 10.38 | 3.58 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 844.90 | 45.32 | -- | -- |
| BioLine RX Ltd | 43.35m | -182.80m | 207.85m | 79.00 | -- | 3.88 | -- | 4.79 | -0.1891 | -0.1891 | 0.0432 | 0.0447 | 0.1939 | -- | 6.40 | 548,729.20 | -81.75 | -52.74 | -127.94 | -65.43 | 55.84 | -- | -421.69 | -3,501.79 | 1.05 | -519.43 | 0.4642 | -- | -- | -- | -142.93 | -- | -50.72 | -- |
| Top Gum Industries Ltd | 178.05m | 15.02m | 604.36m | 202.00 | 19.33 | 2.36 | 26.14 | 3.39 | 0.2891 | 0.2891 | 2.21 | 2.37 | 0.5282 | 3.54 | 2.68 | 881,424.10 | 4.46 | -- | 5.59 | -- | 33.07 | 32.03 | 8.44 | 5.48 | 2.36 | -- | 0.2903 | -- | 3.84 | 25.32 | -11.56 | -- | 82.55 | -- |
| Compugen Ltd | 133.97m | -62.05m | 689.31m | 68.00 | -- | 3.04 | -- | 5.15 | -0.704 | -0.704 | 1.52 | 2.48 | 0.3638 | -- | 11.29 | 1,970,079.00 | -16.85 | -28.41 | -20.51 | -32.57 | 88.60 | 92.40 | -46.32 | -293.48 | -- | -- | 0.00 | -- | 346.12 | 13.45 | 44.34 | -- | 1.71 | -- |
Data as of Jun 16 2024. Currency figures normalised to Bioline Rx Ltd's reporting currency: Israeli Shekel ILS
0.62%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Meitav Mutual Funds Ltd.as of 29 Feb 2024 | 3.33m | 0.28% |
| KSM Mutual Funds Ltd.as of 29 Feb 2024 | 2.58m | 0.22% |
| Dimensional Fund Advisors LPas of 06 Jun 2024 | 817.91k | 0.07% |
| Dimensional Fund Advisors Ltd.as of 30 Apr 2024 | 305.92k | 0.03% |
| Psagot Mutual Funds Ltd.as of 29 Feb 2024 | 235.56k | 0.02% |
| Harel Mutual Funds Ltd.as of 29 Feb 2024 | 112.26k | 0.01% |
More ▼
Data from 29 Feb 2024 - 13 Jun 2024Source: FactSet Research Systems Inc.
